Jahn, Nikolaus
Jahn, Ekaterina
Saadati, Maral
Bullinger, Lars
Larson, Richard A. http://orcid.org/0000-0001-9168-3203
Ottone, Tiziana
Amadori, Sergio
Prior, Thomas W.
Brandwein, Joseph M.
Appelbaum, Frederick R.
Medeiros, Bruno C. http://orcid.org/0000-0001-6972-8137
Tallman, Martin S.
Ehninger, Gerhard
Heuser, Michael http://orcid.org/0000-0001-5318-9044
Ganser, Arnold
Pallaud, Celine
Gathmann, Insa
Krzykalla, Julia
Benner, Axel
Bloomfield, Clara D. http://orcid.org/0000-0001-5465-7591
Thiede, Christian http://orcid.org/0000-0003-1241-2048
Stone, Richard M. http://orcid.org/0000-0002-7526-2633
Döhner, Hartmut
Döhner, Konstanze http://orcid.org/0000-0002-2261-9862
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA196171, U10CA180882, U10CA180861, U10CA180861)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 19 June 2022
Revised: 22 June 2022
Accepted: 4 July 2022
First Online: 3 August 2022
Competing interests
: MS has a collaboration with Boehringer Ingelheim. LB was on advisory committees for AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, and Seattle Genetics, and has received research support from Bayer and Jazz Pharmaceuticals. RAL has acted as a consultant or advisor to Novartis, AbbVie, Amgen, Ariad/Takeda, Astellas, Celgene/BMS, CVS/Caremark, Epizyme, and MorphoSys, and has received clinical research support to his institution from Novartis, Astellas, Celgene, Cellectis, Daiichi Sankyo, Forty Seven, Gilead, and Rafael Pharmaceuticals, and royalties from UpToDate. FRA serves on advisory boards for Adaptive Biotechnology and Jasper Therapeutics. MH received honoraria from Abbvie, Eurocept, Jazz Pharmaceuticals, Janssen, Novartis, Takeda, funding for institution from Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Jazz Pharmaceuticals, Karyopharm, Novartis, Pfizer, Roche, and consults Abbvie, Agios, BMS, Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Tolremo. AG serves on advisory board for Novartis and received research support from Novartis. IG and CP are employees of Novartis. RMS reports personal fees from AbbVie, Actinium, Agios, Argenx, Astellas, AstraZeneca, Biolinerx, Celgene, Daiichi Sankyo, Elevate, Gemoab, Janssen, Jazz, Macrogenics, Novartis, Otsuka, Pfizer, Hoffman LaRoche, Stemline, Syndax, Syntrix, Syos, Takeda, and Trovagene and received research support from AbbVie, Agios, Arog, and Novartis. HD has acted as a consultant or advisor for AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, Bristol-Myers Squibb, Celgene, GEMoaB, Gilead, Janssen, Jazz, Novartis, Servier, Syndax and has received institutional research support from AbbVie, Agios, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis. KD was on advisory committees for Novartis, Janssen Pharmaceutica, Celgene, Bristol-Myers Squibb, and Daiichi Sankyo. The remaining authors declare no competing interests.